# Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）

> **NCT05167994** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 30 (estimated)

## Conditions studied

- Sarcoma,Soft Tissue
- Extremity
- Trunk
- Anlotinib
- Intensity-modulated Radiotherapy
- Major Wound Complications

## Interventions

- **DRUG:** Anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT05167994
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167994, "Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01）". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05167994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*